SCHEMBL1912045

SCHEMBL1912045

Cc1nc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2C(N)=O)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 11/20 0.72
▸ MAPK10 P53779 11/20 0.72
▸ MAPK8 P45983 6/20 0.72
▸ INSR P06213 3/20 0.60
▸ IGF1R P08069 3/20 0.60
▸ PTK2 Q05397 3/20 0.60
▸ PTK2B Q14289 2/20 0.60
▸ PKMYT1 Q99640 1/20 0.60
▸ SLC2A1 P11166 1/20 0.59
▸ EGFR P00533 3/20 0.59
▸ CDK2 P24941 3/20 0.58
▸ CDC7 O00311 2/20 0.58
▸ DAPK3 O43293 2/20 0.58
▸ JAK2 O60674 2/20 0.58
▸ PRKD3 O94806 2/20 0.58
▸ PAK4 O96013 2/20 0.58
▸ SYK P43405 2/20 0.58
▸ CLK2 P49760 2/20 0.58
▸ CDK7 P50613 2/20 0.58
▸ CAMK2D Q13557 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12729770 0.90 PTK2 (0.58) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL12729763 0.88 PTK2 (0.61) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL1912053 0.84 ALK (0.60) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL1912009 0.84 ALK (0.60) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL12893066 0.81 AXL (0.62) INSRIGF1REGFRCDK2ALK
SCHEMBL12729777 0.81 ALK (0.62) INSRPTK2EGFRALKMET
SCHEMBL12917664 0.80 ULK1 (0.53) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL28589740 0.77 EGFR (0.82) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL12729786 0.76 ALK (0.57) MAPK9MAPK10MAPK8INSRIGF1R
SCHEMBL25668162 0.76 EGFR (0.81) MAPK9MAPK10MAPK8INSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660458-B1 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NOVARTIS AG (CH) 2012-01-25 — — EP disclosed
EP-2287156-A1 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders Novartis AG (CH) 2011-02-23 — — EP disclosed
Send feedback